Embryopathy


Also found in: Dictionary, Medical.
Related to Embryopathy: teratogenic, rubella embryopathy

embryopathy

[‚em·brē′äp·ə·thē]
(medicine)
Any abnormal development of an embryo, either morphological or biochemical.

Embryopathy

 

a disease of or injury to a human embryo occurring between the middle of the first and the end of the third month of intrauterine development. Embryopathy may be caused by a genetic disturbance or by a pathogenic factor that affects the embryo through the mother, such as hypoxia, poisoning, or an infectious disease. Embryopathy may result in malformation of embryonic organs, developmental anomalies, and spontaneous abortion. Prevention calls for the protection of the mother’s health during the first months of pregnancy.

Mentioned in ?
References in periodicals archive ?
Adverse effects of warfarin in the fetus Warfarin embryopathy (6-12 weeks) Nasal hypoplasia Stippled epiphyses Saddle-nose deformity Mental retardation Optic atrophy Frontal bossing Hypertelorism High-arched palate Short neck Short stature Fetal effects (all trimesters and delivery) Ocular abnormalities-blindness Neurological abnormalities-microcephaly, mental retardation, low intelligent quotients Fetal loss Bleeding Table 6.
The most popular management strategy in the United States entails a switch from warfarin to unfractionated heparin as soon as pregnancy is diagnosed, with a switch back to warfarin at 13 weeks' gestation, after the risk of embryopathy is over.
Warfarin throughout pregnancy is a particularly attractive strategy in a high-risk woman who was well controlled on the anticoagulant at 5 mg/day or less prior to pregnancy, which might lessen the risk of warfarin embryopathy, she continued.
Diabetic embryopathy accounts for about 40% of deaths of infants of diabetic mothers.
Embryopathy was usually caused by oral anticoagulant use during the first trimester, whereas anticoagulant use during the second and third trimesters was associated with a high fetal loss rate.
Although MMI offers the advantage of a longer half-life and, thus, single daily dosing, it has been associated with rare cases of congenital fetal abnormalities, including scalp defects and methimazole embryopathy.
The chief downside of warfarin use in pregnancy is the risk of embryopathy with fetal exposure during weeks 6-9.
Accutane does not affect sperm, and there is no evidence from studies that Accutane embryopathy can result from exposed sperm.
The key issue is which drug is better able to prevent valve thrombosis and still avoid embryopathy and fetal wastage.
This explanation, rather than inflammatory or metabolic mechanisms, clarifies the specificity of thalidomide embryopathy and has significant implications for its therapeutic application.